gilteritinib
Kura Oncology Begins Testing Menin Inhibitor With Standard Therapies in Phase I AML Trial
The KOMET-008 trial of ziftomenib combinations will involve AML patients harboring either NPM1 mutations or KMT2A rearrangements.
Arog Pharma Moving FLT3 Inhibitor Crenolanib Into Head-to-Head AML Trial Against First-Gen Rydapt
Premium
A Phase II trial of crenolanib plus chemo in FLT3-mutant AML demonstrated a robust complete response rate, particularly in younger patients.
FDA Clears Oryzon's IND for Phase Ib Trial of Iadademstat in FLT3-Mutant AML
The company will enroll approximately 45 patients and explore the activity of the LSD1 inhibitor iadademstat with Astellas' FLT3 inhibitor Xospata.
Astellas' Xospata Receives Conditional Approval in Refractory AML in China
China's National Medical Products Administration granted conditional approval based on results from a Phase III study in FLT3-mutated AML patients.
Astellas' Xospata Fails to Extend Survival in Phase III Newly Diagnosed AML Trial
An independent data monitoring committee recommended terminating the study and Astellas has stopped enrollment after the drug failed to meet its primary endpoint.
Apr 10, 2020
Astellas' NDA for Xospata Accepted by NMPA in China
Mar 12, 2019
Nov 27, 2018